Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 3, 2006, Pages 843-850

  Kupelian, Varant ^a   Page, Stephanie T ^b   Araujo, Andre B ^a   Travison, Thomas G ^a   Bremner, William J ^a   McKinlay, John B ^a,b  

^a NEW ENGLAND RESEARCH INSTITUTES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL OBESITY; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONOBESE MALE; OBESITY; POISSON DISTRIBUTION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; WEIGHT CONTROL;

ADULT; AGED; ANDROGENS; BODY WEIGHT; CARDIOVASCULAR DISEASES; COHORT STUDIES; HUMANS; MALE; MASSACHUSETTS; METABOLIC SYNDROME X; MIDDLE AGED; REFERENCE VALUES; SEX HORMONE-BINDING GLOBULIN; SOCIOECONOMIC FACTORS; TESTOSTERONE;

EID: 33644828241     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1326     Document Type: Article

References (45)

1. 2005 Heart disease and stroke statistics: 2005 update. Dallas: American Heart Association
2. Harris MI, Klein R, Welborn TA, Knuiman MW 1992 Onset ofNIDDMoccurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15:815-819
3. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM 2003 The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26:3153-3159
4. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J 2003 Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414-419
5. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB 2002 Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87:589-598
6. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR 2001 Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724-731
7. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW 2000 Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 85:3276-3282
8. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ 2004 Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 27:861-868
9. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB 2000 Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 23:490-494
10. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L 1996 Low levels of sex hormone-binding globulin and testosterone predict the development of noninsulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 143:889-897
11. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH 1997 Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 146:609-617
12. Wu FC, von Eckardstein A 2003 Androgens and coronary artery disease. Endocr Rev 24:183-217
13. Wu FC, Farley TM, Peregoudov A, Waites GM 1996 Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril 65:626-636
14. Meriggiola MC, Marcovina S, Paulsen CA, Bremner WJ 1995 Testosterone enanthate at a dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int J Androl 18:237-242
15. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL 2005 Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502-1510
16. Snyder PJ, Peachey H, Berlin JA, Rader D, Usher D, Loh L, Hannoush P, Dlewati A, Holmes JH, Santanna J, Strom BL 2001 Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med 111:255-260
17. Sader MA, Griffiths KA, Skilton MR, Wishart SM, Handelsman DJ, Celermajer DS 2003 Physiological testosterone replacement and arterial endothelial function in men. Clin Endocrinol (Oxf) 59:62-67
18. Ong PJ, Patrizi G, Chong WC, Webb CM, Hayward CS, Collins P 2000 Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol 85:269-272
19. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT 2005 Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 90:2618-2623
20. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT 2004 Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036-1041
21. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry III HM 2000 Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49:1239-1242
22. Summary from the 2nd Annual Andropause Consensus Meeting. The Endocrine Society, 2001. www.endo-society.org/publicpolicy/legislative/upload/ andro_cc_summary.pdf (last accessed 12/20/05)
23. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB 2004 Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 89:5920-5926
24. O'Donnell AB, Araujo AB, McKinlay JB 2004 The health of normally aging men: The Massachusetts Male Aging Study (1987-2004). Exp Gerontol 39:975-984
25. McKinlay S, Kipp D, Johnson P, Downey K, Carelton R, A field approach for obtaining physiological measures in surveys of general populations: response rates, reliability and costs. Proc 4th Conference on Health Survey Research Methods, Washington, DC, 1984
26. McEvoy G 1989 American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Hospital Pharmacists
27. Alberti KG, Zimmet PZ 1998 Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553
28. 2001 Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
29. Brambilla DJ, McKinlay SM, McKinlay JB, Weiss SR, Johannes CB, Crawford SL, Longcope C 1996 Does collecting repeated blood samples from each subject improve the precision of estimated steroid hormone levels? J Clin Epidemiol 49:345-350
30. Matsumoto AM 2002 Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 57:M76-M99
31. Lunenfeld B, Saad F, Hoesl CE 2005 ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male 8:59-74
32. Szklo M, Nieto J 2000 Epidemiology: beyond the basics. Gaithersburg, MD: Aspen
33. National Institutes of Health 1998 Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 6(Suppl 2):51S-209S
34. Khaw KT, Barrett-Connor E 1992 Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 2:675-682
35. Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, Papoz L 1992 Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 35:173-177
36. Haffner SM, Karhapaa P, Mykkanen L, Laakso M 1994 Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 43:212-219
37. Tchernof A, Labrie F, Belanger A, Prud'homme D, Bouchard C, Tremblay A, Nadeau A, Despres JP 1997 Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis 133:235-244
38. Crave JC, Lejeune H, Brebant C, Baret C, Pugeat M 1995 Differential effects of insulin and insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (Hep G2) cells. J Clin Endocrinol Metab 80:1283-1289
39. Plymate SR, Matej LA, Jones RE, Friedl KE 1988 Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 67:460-464
40. Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S, Chierici R, Flamia R, Biscotti M, Vicennati V 1995 Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 80:654-658
41. Katsuki A, Sumida Y, Murashima S, Fujii M, Ito K, Tsuchihashi K, Murata K, Yano Y, Shima T 1996 Acute and chronic regulation of serum sex hormone-binding globulin levels by plasma insulin concentrations in male noninsulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab 81:2515-2519
42. Lindstedt G, Lundberg PA, Lapidus L, Lundgren H, Bengtsson C, Bjorntorp P 1991 Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-yr follow-up of population study of women in Gothenburg, Sweden. Diabetes 40:123-128
43. Yki-Jarvinen H, Makimattila S, Utriainen T, Rutanen EM 1995 Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. J Clin Endocrinol Metab 80:3227-3232
44. Birkeland KI, Hanssen KF, Torjesen PA, Vaaler S 1993 Level of sex hormonebinding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 76:275-278
45. Matthews JN, Altman DG 1996 Statistics notes. Interaction 2: compare effect sizes not P values. Br Med J 313:808